Indapamide and Chlorthalidone to Reduce Urine Supersaturation for Kidney Stone Prevention - Trial NCT06111885
Access comprehensive clinical trial information for NCT06111885 through Pure Global AI's free database. This Phase 2 trial is sponsored by Insel Gruppe AG, University Hospital Bern and is currently Not yet recruiting. The study focuses on Kidney Stone. Target enrollment is 99 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
Insel Gruppe AG, University Hospital Bern
Timeline & Enrollment
Phase 2
Apr 01, 2024
Jun 01, 2027
Primary Outcome
Primary outcome component 1 - calcium oxalate supersaturation in urine,Primary outcome component 2 - calcium phosphate supersaturation in urine
Summary
The aim of this study is to test the efficacy of the two long-acting thiazide-like diuretics
 indapamide and chlorthalidone in reducing urine supersaturation for calcium oxalate and
 calcium phosphate compared to the short-acting thiazide diuretic hydrochlorothiazide for the
 prevention of calcium-containing kidney stones.
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT06111885
Non-Device Trial